H.C. Wainwright raised the firm’s price target on Zevra Therapeutics to $18 from $15 and keeps a Buy rating on the shares following the positive FDA panel vote for arimoclomol. The firm projects approval, and $250M peak sales in the U.S. alone.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZVRA:
- FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C
- FDA Genetic Metabolic Diseases Advisory Committee holds a meeting
- Zevra Therapeutics to Report Second Quarter 2024 Financial Results
- Zevra Therapeutics Announces Key Agreement Updates and Stock Offering
- Zevra Therapeutics Approaches Key FDA Review and PDUFA Date